Magazine article Drug Topics

VHA Boards Bergen Brunswig's 'Intelligent' Bandwagon

Magazine article Drug Topics

VHA Boards Bergen Brunswig's 'Intelligent' Bandwagon

Article excerpt

A one-year agreement signed last month between Bergen Brunswig Drug Co. and VHA Inc. will focus on reducing costs and improving services through the use of high-tech information management and analysis. VHA, a network of community-owned health-care organizations comprising about a quarter of the nation's community hospitals, will use Bergen Brunswig's Intelligent Drug Information (IDI) program at several sites nationwide to determine "best practices" benchmarks.

"It's a question of taking a series of snapshots and looking at how the membership is using a particular product or group of products, such as a therapeutic class," explained Scott Iteen, Pharm.D., national director of IDI for the Bergen Brunswig Drug Co., a subsidiary of Bergen Brunswig Corp. "From there, you look at opportunities to improve, so that your contracting and formulary process starts taking on more of a fact-based program," he said.

"We wanted to provide our directors of pharmacy with additional tools to help them get a better understanding of their product usage and how to better use standardization and utilization practices to reduce their cost," said Larry Dooley, v.p.-distribution for VHA.

After learning about IDI, Dooley approached VHA's corporate pharmacy team with the original proposal to try the program. "Other companies," he said, "may want to do the evaluation from an outsource perspective, whereas a director of pharmacy can do it himself, with the help of Bergen Brunswig. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.